

**Related Party Disclosures****i. Parties where control exists:**

- a) Sanofi S.A. France, ultimate holding Company
- b) Hoechst GmbH, Germany, holding Company

**ii. Other related parties in Sanofi Group where common control exists and with whom transactions have taken place during the reporting**

Sanofi-Aventis Singapore Pte. Limited  
 Francopia S.A.R.L.  
 Sanofi-Aventis Deutschland GmbH  
 Sanofi-Aventis Groupe  
 Sanofi Lanka Limited\*  
 Sanofi Chimie S.A.\*  
 Sanofi-aventis Philippines Inc.\*  
 Sanofi Healthcare India Private Limited  
 Sanofi Winthrop Industrie S.A.  
 Sanofi US Services Inc.\*  
 Aventis Pharma UK Investments Ltd.\*  
 Sanofi Vietnam Shareholding Company  
 Sanofi-Aventis Gestion S.A.  
 Sanofi-aventis Healthcare Pty Ltd\*  
 Euro API Germany GMBH  
 Sanofi Industries South Africa (PTY) Ltd.  
 SSP Co. Ltd  
 Sanofi India Limited Provident Fund  
 \* No transactions during the year

**iii. Key management personnel of the Company for the year**

Mr. Rodolfo Hrosz - Managing Director (w.e.f June 01, 2022)  
 Mr. Rajaram Narayanan - Managing Director (till the closure of business hours of April 10, 2022)  
 Mr. Cherian Mathew - Whole Time Director  
 Mr. Vaibhav Karandikar - Chief Financial officer and Whole time director (w.e.f February 23, 2021)  
 Mr. Girish Telchandani - Company Secretary (till the closure of business hours of August 31, 2021)  
 Ms. Radhika Shah - Company Secretary (w.e.f November 01, 2021)

**iv. Non-Executive Directors**

Mr. Marc-Antoine Lucchini  
 Mr. Charles Billard - (till the closure of business hours of November 3, 2022)  
 Ms. Annapurna Das - (w.e.f November 3, 2022)

**v. Independent Directors**

Mr. Aditya Narayan  
 Mrs. Usha Thorat  
 Mr. Rahul Bhatnagar

**vi. Transactions during the year**

(₹ in Million)

Particulars	December 31, 2022
<b>Ultimate Holding Company</b>	
Dividend paid	1
Expenses recharged	(2)
<b>Total</b>	<b>(1)</b>
<b>Holding Company</b>	
Dividend paid	2,684
<b>Other related Parties</b>	
<b>Sale of Products and Other Operating Income</b>	
Sanofi-Aventis Singapore Pte. Limited	2,002
Others	81
<b>Total</b>	<b>2,084</b>
<b>Purchase of Raw Materials and Stock- in- trade</b>	
Sanofi-Aventis Singapore Pte. Limited	1,087
Francopia S.A.R.L.	1,106
Sanofi Healthcare India Private Limited	1,241
Others	
<b>Total</b>	<b>3,434</b>
<b>Expenses recharged to other companies</b>	
Sanofi-Aventis Groupe S.A.	1
Sanofi Healthcare India Private Limited	(0)
Sanofi-Aventis Gestion S.A.	4
Others	*
<b>Total</b>	<b>5</b>
<b>Sale of Services</b>	
Sanofi Healthcare India Private Limited	728
Sanofi-Aventis Singapore Pte. Limited	(55)
Others	4
<b>Total</b>	<b>677</b>
<b>Purchase of Tangible Asset</b>	
Sanofi-Aventis Deutschland GmbH	20
<b>Payment towards Intangibles under development</b>	
Sanofi Healthcare India Private Limited	7
<b>Rent Income</b>	
Sanofi Healthcare India Private Limited	1
<b>Rent Paid</b>	
Sanofi Healthcare India Private Limited	0
<b>Loans repaid</b>	
Sanofi Healthcare India Private Limited	4,450
<b>Total</b>	<b>4,450</b>
<b>Interest income on loans</b>	
Sanofi Healthcare India Private Limited	16
<b>Total</b>	<b>16</b>
<b>Expenses recharged by other companies</b>	
Sanofi Healthcare India Private Limited	43
Sanofi-Aventis Groupe S.A.	(3)
Others	0
<b>Total</b>	<b>40</b>
<b>Contribution to In-house Trust for Post Employment Benefits - Provident Fund</b>	
Sanofi India Limited Provident Fund #	323

# Including contribution by employees.  
 \* denotes figure less than a million

(₹ in Million)	
Particulars	December 31, 2022
<b>Key Management Personnel Remuneration # #</b>	
<b>Remuneration</b>	
Mr. Vaibhav Karandikar	7
Mr. Cherian Mathew	10
Mr. Rudolf Hrosz	16
Ms. Radhika Shah	5
<b>Total</b>	<b>38</b>

<b>Share based benefit</b>	
Mr. Vaibhav Karandikar	2
Mr. Rudolf Hrosz	5
Mr. Cherian Mathew	3
<b>Total</b>	<b>10</b>

# # Excludes Provision for Employee Benefits

<b>Loan given</b>	
Mr. Vaibhav Karandikar (Refer note 2 below)	*
<b>Loan repaid</b>	
Mr. Vaibhav Karandikar	*

Particulars	December 31, 2022
<b>Sitting Fees to Non- Executive Directors</b>	
Mr. Aditya Narayan	0
Ms. Usha Thorat	1
Mr. Rahul Bhatnagar	1
<b>Total</b>	<b>1</b>
<b>Commission to Non - Executive Directors</b>	
Mr. Aditya Narayan	0
Ms. Usha Thorat	0
Mr. Rahul Bhatnagar	0
<b>Total</b>	<b>0</b>

\* denotes figure less than a million

#### Terms and conditions of transactions with related parties

The sales, services and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. For the period ended December 31, 2022, the Company has not recorded any impairment of receivables relating to amounts owed by related parties (December 31, 2021: Nil). This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

(₹ in Million)	
Particulars	December 31, 2022
<b>vii. Outstanding as at December 31, 2022</b>	
<b>Trade Receivables</b>	
Sanofi-Aventis Singapore Pte. Limited	736
Sanofi Healthcare India Private Limited	128
Others	8
<b>Total</b>	<b>872</b>
<b>Trade Payables</b>	
Sanofi-Aventis Singapore Pte. Limited	533
Sanofi Winthrop Industrie S.A.	-
Francopia S.A.R.L.	789
Sanofi Healthcare India Private Limited	224
Others	23
<b>Total</b>	<b>1,569</b>
<b>Other Financial Liabilities</b>	
Sanofi Healthcare India Private Limited	7
<b>Loan receivable</b>	
Sanofi Healthcare India Private Limited (Refer Note 1 below)	-
<b>Key Management Personnel</b>	
<b>Loan receivable</b>	
Mr. Vaibhav Karandikar (Refer Note 2 below)	*

1) Loan given to Sanofi Healthcare India Private Limited. The rate of interest was 7.5% till April 14, 2021 and 5.5% from April 15, 2022. Maximum balance outstanding during the year ₹ 4,450 Million (December 31, 2021 : ₹ 4,450 Million) from Sanofi. The said loan has been proposed to be utilized by Sanofi Healthcare India Private Limited for business purpose and was fully recovered.

The Loan was given against corporate guarantee by Sanofi S.A. France. Guarantee is valid till April 15, 2023.

2) Given as per the Company's policies for employees. These are interest free loan and repayable in 12 month equal installments.